Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)

被引：0
|
作者：
Pemmaraju, Naveen [1 ]
Kantarjian, Hagop [2 ]
Shan, Jianqin [2 ]
Jabbour, Elias [2 ]
Quintas-Cardama, Alfonso
Verstovsek, Srdan
Ravandi, Farhad
Wierda, William G. [2 ]
O'Brien, Susan [2 ]
Cortes, Jorge E. [2 ]
机构：
[1] MD Anderson, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：527 / 528
页数：2
相关论文
共 50 条
  • [21] Outcomes of blast phase chronic myeloid leukemia (BP-CML) in the tyrosine kinase inhibitor (TKI) era.
    Talati, Chetasi
    Isenalumhe, Leidy Lismeri
    Shams, Samantha Reiter
    Kuykendall, Andrew Tucker
    Chavez, Julio C.
    Shah, Bijal D.
    Sweet, Kendra Lynn
    Pinilla-Ibarz, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Wierda, William G.
    Daver, Naval
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Jain, Preetesh
    Rios, Mary B.
    Pierce, Sherry
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [23] Incidence and outcomes of chronic myeloid leukemia (CML) patients (pts) treated with second-generation tyrosine kinase inhibitors (TKI) who develop other chromosomal abnormalities (OCA).
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Burton, Elizabeth M.
    Dellasala, Sara
    Pierce, Sherry
    Kornblau, Steven Mitchell
    Verstovsek, Srdan
    O'Brien, Susan Mary
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP)
    Ohanian, Maro
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Burton, Elizabeth M.
    Trinh, Long Xuan
    Ferrajoli, Alessandra
    Jabbour, Elias
    Kadia, Tapan
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1614 - 1615
  • [25] Treatment Responses in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors (TKI) Therapy
    Mir, Ahmed Ali
    Mir, Abdur Rehman
    Rehmat, Uswah
    Shakoor, Ifra
    Amjad, Farhan
    Khalid, Muhammad
    Mallhi, Tauqeer Hussain
    Laique, Talha
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (09): : 2358 - 2360
  • [26] Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Ravandi, Farhad
    Nogueras-Gonzalez, Graciela M.
    Huang, Xuelin
    O'Brien, Susan
    Wierda, William
    Garcia-Manero, Guillermo
    Thomas, Deborah
    Pierce, Sherry
    Verstovsek, Srdan
    Borthakur, Gautam
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (04): : 213 - +
  • [27] Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).
    McGarry, Lisa J.
    Burudpakdee, Chakkarin
    Gala, Smeet
    Seetasith, Arpamas
    Nanavaty, Merena
    Huang, Hui
    BLOOD, 2014, 124 (21)
  • [28] No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
    Iglesias, Lilian
    Mukherjee, Sudipto
    Nazha, Aziz
    Advani, Anjali S.
    Gerds, Aaron T.
    Carraway, Hetty E.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Majhail, Navneet S.
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
  • [29] Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors
    Sasaki, Koji
    Jabbour, Elias
    Issa, Ghayas C.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Wierda, William G.
    Yilmaz, Musa
    DiNardo, Courtney D.
    Skinner, Jeffrey
    Khouri, Maria
    Pemmaraju, Naveen
    Nasnas, Patrice
    Pierce, Sherry A.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
  • [30] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence
    Ciftciler, R.
    Haznedaroglu, I. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (24) : 7787 - 7798
12345